Stay updated on Nivolumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no impact on study content or functionality.
    Difference
    0.0%
    Check dated 2026-03-11T17:56:19.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Deleted: the government funding lapse notice and the earlier Revision: v3.4.1; these are administrative changes and do not affect the study content, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T03:08:44.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    A funding/operational status notice was added, and the site revision tag updated to v3.4.1, replacing the previous v3.4.0 tag.
    Difference
    0.3%
    Check dated 2026-02-04T01:37:22.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    UI changes include showing the glossary and adding a QC metadata line (Last Update Submitted that Met QC Criteria). The revision number was updated to v3.4.0 and No FEAR Act Data labeling was adjusted.
    Difference
    0.2%
    Check dated 2026-01-28T00:20:08.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4. The study details and layout remain unchanged.
    Difference
    0.0%
    Check dated 2026-01-14T02:35:06.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    An administrative change was made: a new Revision: v3.3.3 was added and the HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the page footer. The study content, eligibility criteria, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T14:24:52.000Z thumbnail image

Stay in the know with updates to Nivolumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.